$JAZZ News

Jazz Pharmaceuticals plc (JAZZ) Presents at Jefferies Global Healthcare Conference 2026 Transcript

Jazz Pharmaceuticals PLC (JAZZ): CBD-Based Epidiolex Drug Sales Up 15%

Insider Decision: Rick E Winningham Exercises Options At Jazz Pharmaceuticals For $341K

Phase 3 HERIZON-GEA-01 Results Published in The New England Journal of Medicine Show Durable and Consistent Survival Benefit with Ziihera® (zanidatamab-hrii) Combinations in First-Line HER2+ Locally Advanced or Metastatic GEA

Jazz Pharmaceuticals plc (JAZZ) Presents at TD Cowen's 7th Annual Oncology Innovation Summit: Insights for ASCO & EHA Transcript

Barclays Maintains Overweight on Jazz Pharmaceuticals, Raises Price Target to $253

Banking giant massively resets Jazz Pharma stock price target

Assessing Jazz Pharmaceuticals (JAZZ) Valuation After Its Recent Share Price Momentum

Morgan Stanley Raises its Price Target on Jazz Pharmaceuticals (JAZZ)

Bernstein Initiates Coverage On Jazz Pharmaceuticals with Market Perform Rating, Announces Price Target of $229

Piper Sandler Maintains Overweight on Jazz Pharmaceuticals, Raises Price Target to $301

UBS Just Upgraded Jazz Pharma to Buy. New $307 Price Target Could Signal a Turning Point

UBS Upgrades Jazz Pharmaceuticals to Buy, Raises Price Target to $307

Jazz Pharmaceuticals plc (JAZZ) Presents at RBC Capital Markets Global Healthcare Conference 2026 Transcript

Jazz Pharmaceuticals’s Q1 Earnings Call: Our Top 5 Analyst Questions

Does Epidiolex Make Jazz Pharmaceuticals a Unique Cannabis Stock?

Some Investors May Be Willing To Look Past Jazz Pharmaceuticals' (NASDAQ:JAZZ) Soft Earnings

Here’s What Analysts Are Saying About Jazz Pharmaceuticals (JAZZ) Post Q1 Results

Jazz Pharmaceuticals to Participate in Upcoming Investor Conferences

International Markets and Jazz (JAZZ): A Deep Dive for Investors